Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tobramycin · Bethkis, NSC-180514

Small molecule · developed by Chiesi Usa

Approved FDA
1 Registered trials

What is Tobramycin?

Tobramycin is an inhaled aminoglycoside antibacterial. It is studied in Pseudomonas aeruginosa infection, including in patients with cystic fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Bethkis, NSC-180514
Drug type
Small molecule
Therapy area
Infectious disease, Respiratory
Developer
Chiesi Usa, Inc.
In trials of
INSM
FDA status
Approved as Bethkis, NDA201820 · FDA label
UNII
VZ8RRZ51VK

✅ FDA-approved uses

From the indications section of the FDA label (version of Feb 24, 2023). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01315678 Phase 3 Pseudomonas Aeruginosa Infection Completed INSM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Pseudomonas Aeruginosa Infection

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.